問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chiayi Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Radiology

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間：2023-09-19

蔡熒煌Tsai, Ying-Huang
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 10 個月

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡熒煌

List

28Cases

2007-11-14 - 2009-12-29

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2007-10-01 - 2008-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-10-15 - 2011-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2017-05-01 - 2020-07-31

Phase III

Active
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

  • Condition/Disease

    Non Small-Cell Lung Cancer (NSCLC)

  • Test Drug

    Durvalumab / Tremelimumab

Participate Sites
10Sites

Recruiting1Sites

Terminated9Sites

羅永鴻
Taipei Veterans General Hospital

Division of Thoracic Medicine

2018-01-15 - 2029-06-30

Phase III

Active
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    Pembrolizumab (MK-3475) / 商品名：KEYTRUDA/吉舒達

Participate Sites
7Sites

Recruiting4Sites

Terminated1Sites

2015-02-19 - 2019-06-25

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

Suspended1Sites

2016-09-19 - 2019-08-23

Phase II/III

Completed
Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)

  • Condition/Disease

    methothlioma

  • Test Drug

    ADI-PEG 20

Participate Sites
7Sites

Terminated6Sites

鍾飲文
Kaohsiung Municipal Gangshan Hospital

未分科

2007-11-14 - 2009-12-29

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2017-08-24 - 2019-09-30

Phase III

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

  • Condition/Disease

    Small-Cell Lung Cancer (SCLC)

  • Test Drug

    Durvalumab; Tremelimumab

Participate Sites
11Sites

Terminated10Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

夏德椿
China Medical University Hospital-Taipei

未分科

2009-02-01 - 2017-05-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated3Sites

Suspended4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB